Cipla releases financial results for FY19
The profit after tax (PAT) for Q4 stood at Rs 367 Cr and for FY19 stood at Rs 1528 Cr
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Latest Updates
Zydus Cadila gets USFDA nod for acid reflux drug
The drug, esomeprazole, belongs to the group of medicines termed as proton pump inhibitors and reduces the amount of acid secreted…
Health Canada approves Biocon and Mylan’s Ogivri for cancer treatment
Ogivri is the first trastuzumab biosimilar approved in Canada and the second biosimilar from Biocon and Mylan’s joint portfolio…
PharmaLytica to be held in Mumbai in June
The event will witness the participation of over 300 exhibitors from across the country and outside, including notable industry…
Low-cost method to store, transport life-saving vaccines developed
The new method, described in the journal Scientific Reports, combines ingredients in existing vaccines with a sugary gels,…
Lupin launches Budesonide Inhalation Suspension
Lupin’s Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules is a generic version of AstraZeneca Pharmaceuticals LP’s…
AbbVie halts enrollment after brain cancer trial misses goal, shares fall
The trial has been testing the drug, Depatux-M, to treat an aggressive form of brain cancer known as glioblastoma
Thermo Fisher Scientific inaugurates new facility in Ahmedabad
The state-of-the art facility in the domestic tariff area (DTA) is part of Thermo Fisher’s clinical trials business and was built…
WuXi STA and Dizal sign CMC Development and Manufacturing Agreement
WuXi STA will now provide Dizal integrated CMC (Chemical, manufacturing and Control) process research and manufacturing services…
Torrent Pharma posts Q4 net loss of Rs 152 cr
Also, for the fiscal year ended March 2019, the company posted a net profit of Rs 436 crore as against Rs 678 crore for the…
Glenmark gets US FDA nod for Solifenacin Succinate Tablets
The US FDA approved the Abbreviated New Drug Application for Solifenacin Succinate Tablets, which are a generic version of…
GlaxoSmithKline reports an eight per cent revenue growth for FY19
The company recently released its consolidated financial results, wherein it reported a 21 per cent hike in net revenue for FY19
Dr Reddy’s to spend up to USD 300 mn on R&D in FY 2019
The R&D spend for the quarter (January-March FY 19) is Rs 366 crore, that is USD 53 million and EBIT 9.19 per cent of the…
AstraZeneca moves US court against Aurobindo Pharma on generic
The AstraZeneca alleged that the Indian drug makers proposed generic Daliresp would infringe the patents on three counts and…
TAKE Solution announces consolidated financial results
The company reported a 28.5 per cent growth in revenues at Rs 20,390 mn and a growth of 11.6 per cent in net profits for FY19;…
Jubilant Life Sciences announces consolidated financial results for Q4 & 12M’FY19 Results
The company reported a 21 per cent hike in YoY total revenue at Rs. 9,111 Crore
Dr Reddy’s Q4 PAT up 44 per cent at Rs 434 crore
The revenue for the quarter under discussion was up by 14 per cent at Rs 4,016.60 crore against Rs 3,534.90 crore in the same…
Changing brand name mandatory when changing drug composition: CDSCO
The drug regulator stated that the practice of changing the key therapeutic ingredients in a drug formulation without changing the…
Shilpa Medicare gets USFDA nod for cancer drug
The company has received US FDA final approval for its ANDA for Docetaxel Injection USP in the strengths of 20 mg/mL, 80 mg/4 mL…
Biocon and Mylan to announce the final overall survival data for Ogivri
Ogivri is the first biosimilar for Herceptin approved by the US Food and Drug Administration (FDA) for all indications including…